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a  b  s  t  r  a  c  t
Hepatic  sinusoidal  obstruction  syndrome  (HSOS)  is  a hepatic  vascular  disease  histologically  characterized
by  edema,  necrosis,  detachment  of  endothelial  cells  in small  sinusoidal  hepatic  and  interlobular  veins  and
intrahepatic  congestion,  which  leads  to  portal  hypertension  and  liver  dysfunction.  In  the Western  world,
most  HSOS  cases  are  associated  with  myeloablative  pretreatment  in  a hematopoietic  stem  cell  transplan-
tation  setting.  Here  we  report  a case  of a 54  years  old  female  patient,  otherwise  healthy,  with  no history
of alcoholic  ingestion,  who  presented  with  jaundice  and  signs  of portal  hypertension,  including  ascites
and  bilateral  pleural  effusion.  She had  no history  of  liver disease  and  denied  any  other  risk  factor  for liver
injury,  except  Senecio  brasiliensis  ingestion  as a tea,  prescribed  as  a therapy  for menopause.  Acute  viral
hepatitis  and  thrombosis  of the  portal  system  were  excluded  in  complementary  investigation,  as  well  as
sepsis, metastatic  malignancy  and  other  liver  diseases,  setting  a RUCAM  score  of 6. Computed  tomogra-
phy  demonstrated  a diffuse  liver parenchymal  heterogeneity  (in mosaic)  and  an  extensive  portosystemic
collateral  venous  circulation,  in  the absence  of  any  noticeable  venous  obstruction.  HSOS  diagnosis  was
confirmed  through  a liver  biopsy.  During  the  following-up  period,  patient  developed  refractory  pleural
effusion,  requiring  hemodialysis.  Right  before  starting  anticoagulation,  she  presented  with  abdominal
pain  and  distention,  with  findings  compatible  of  mesenteric  ischemia  by  computed  tomography.  A laparo-
tomy  was  performed,  showing  an  80 cm  segment  of  small  bowel  ischemia,  and  resection  was  done.  She
died  one  day after  as  a result  from  a  septic  shock  refractory  to  treatment.  The  presented  case  was  related
to  oral  intake  of  S.  brasiliensis,  a plant  containing  pyrrolidine  alkaloids,  which  are  one  of  the  main  causes
of  HSOS  in  the  East,  highlighting  the  risk  of liver  injury  with  herbs  intake.
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1. Introduction
Hepatic sinusoidal obstructive syndrome (HSOS), formerly
known as veno-occlusive disease, is a vascular disease character-
ized by edema, necrosis and detachment of endothelial cells in
small sinusoidal hepatic and interlobular veins, with intrahepatic
congestion, which leads to portal hypertension and liver dysfunc-
tion [1,2]. Because of its presentation, it might be mistaken with
decompensated cirrhosis or other forms of acute liver disease,
which might delay the diagnosis and thus the proper treatment
[3].
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HSOS causes varies between West and East – in the latter it is
ainly associated with oral ingestion of plants containing pyrroli-
ine alkaloid (PA), such as Senecio brasiliensis,  while in the Western
orld it is mostly restricted to the hematopoietic cell transplanta-
ion (HCT) and myeloablative treatment setting [4].
. Case report
We present a case of a white woman, 54 years old, with previous
istory of depression, who was  admitted at a hinterland hospital
ith a report of asthenia and malaise four days before admission.
hen she started with jaundice, she sought medical help and was
romptly hospitalized. The patient denied other comorbidities or
se of medications except the daily use of a homemade tea of S.
rasiliensis, a native plant to fields of South America prescribed by
 S.L.U. This is an open access article under the CC BY-NC-ND license (http://










































Fig. 1. Bilirubin levels.
a healer in the last 20 days as a menopause therapy. Ten days after
admission she was transferred to our hospital liver unit. On admis-
sion, she denied any history of liver disease, alcohol use and had
no liver disease stigmata, as well as no signs of coagulopathy or
encephalopathy. Her physical examination showed signs of ascites
and bilateral pleural effusion. Tests for acute viral infections (IgM
for A and B hepatitis, EBV, HSV, HIV and VZV) were negative, except
for a weak positive IgM serology for cytomegalovirus (CMV). CMV
IgG antibody affinity was  high, with a low CMV  viral load, findings
interpreted as possible reactivation in a context of critical disease.
Autoantibodies, iron and copper metabolism tests performed at
admission were also negative. Laboratory values from admission
were: aspartate aminotransferase 585, alanine aminotransferase
264, total bilirubin 5.08, alkaline phosphatase 293, -glutamyl
transferase 452, prothrombin time 15.7s (reference 13s), 175,000
platelets and factor V of 65%.
Abdominal ultrasound showed a normal sized spleen, liver
with normal dimensions, smooth contours, discrete heterogeneous
echogenicity, periportal edema, portosystemic collateral venous
circulation, moderate amount of ascitic fluid and no signs of
thrombosis of the hepatic venous portal system and tributaries.
Afterwards, thorax and abdominal computed tomography (CT)
revealed moderate bilateral pleural effusion, with no signs of
parenchymal disease, while liver showed irregular surface, fissures
enlargement, heterogeneity, with portosystemic circulation and
paraumbilical vein recanalization, perigastric and periesophageal
varices. Portal vein diameter was 1.5 cm (normal 1.2 cm)  and there
was a voluminous ascites.
Calculated RUCAM score (Roussel Uclaf Causality Assessment
Method), a tool used for quantitatively assess causality in cases of
suspected drug or herbal liver injury [5], was 6, compatible with
probable injury related to the herbal (2 points for time to onset –
between 5 and 90 days, 2 points on course of ALP after drug ces-
sation – 452 initially, 185 twenty days later, 2 points for reaction
labeled in the product characteristics).
Ascites and pleural effusion were sent to analysis on the first
day, and were compatible with transudate, with a high serum-
ascites albumin gradient (SAAG) – 1.7. Neutrophil count was higher
than 250, and patient was treated as having spontaneous bacte-
rial peritonitis, although there was no clear evidence of cirrhosis.
Eleven days after admission, she developed a septic shock, evolv-
ing with acute respiratory distress syndrome, requiring mechanic
ventilation. Her clinical picture improved partially, with extuba-
tion, but worsening of mental status (grade II encephalopathy) and
persistent renal disfunction, progressing into oliguria and hydro-
electrolytic dysbalance, demanding hemodialysis fourteen days
after admission. The laboratory curves are shown in Figs. 1 and 2.
Considering the severity involving the scenario, in spite of





Fig. 2. Aminotransferase levels.
osis, the patient was  submitted to a liver biopsy, which showed a
istologic pattern compatible with veno-occlusive disease (Fig. 3).
efore starting anticoagulation, in twenty-four days of hospitaliza-
ion, her clinical state suddenly got worse, showing signs of shock,
bdominal distention and pain, along with fecaloid vomit. Urgent
T showed signs of mesenteric ischemia, confirmed by exploratory
aparotomy, with resection of an 80 cm necrotic small bowel area.
hortly afterwards, despite support, patient evolved to multiple
rgan dysfunction and death, on the twenty-fifth day of admission.
. Discussion
HSOS has two  major causes: cytotoxic or immunosuppressive
gents, such as cyclophosphamide, and the ingestion of pyrrolidine
gents, such as S. brasiliensis.  The syndrome should be suspected
n patients with significant portal hypertension in the absence
f cirrhosis. Differential diagnosis include Budd-Chiari syndrome,
epatic injury induced by another drugs, acute alcoholic hepatitis,
nd, in selected cases, decompensated cirrhosis [6].
The main clinical symptoms of patients with PA-HSOS is highly
imilar to those with HCT-HSOS [7]. The diagnosis of PA-HSOS is
ased on the patient’s history of illness, clinical manifestations,
maging results and pathological features. To facilitate the diagno-
is of HCT-HSOS, two  different sets of clinical criteria have been
escribed: the revised Seattle and the Baltimore criteria. These
re based on the presence of clinical findings (jaundice, weight
ain, hepatomegaly and ascites) not attributable to any other pos-
ible cause, in the first 3 weeks after HCT [8]. The treatment of
A-HSOS is mainly based on anticoagulation and antithrombotic
gents in addition to supportive and liver protective treatments.
lthough regular heparin or low molecular weight heparin has a
trong anticoagulant effect in thrombotic diseases, it has no signif-
cant preventive or therapeutic effect in patients with HCT and it
ncreases the risk of bleeding [7]. As a result, regular heparin or low
olecular weight heparin is not recommended for the treatment of
CT-HSOS [9]. The efficacy of Transjugular Intrahepatic Portosys-
emic Shunt (TIPS) for PA-HCT is controversial. Patients with HCT
sually have serious underlying diseases that can affect the efficacy
f TIPS [7].
Pyrrolizidine alkaloids are a group of naturally occurring
lkaloids based on the structure of pyrrolizidine. The precise mech-
nism of hepatic injury is unknown but appears to result from
ccumulation of highly reactive electrophilic metabolites produced
ia P450 cytochrome enzyme system. The increased concentration
f P450 enzymes within the hepatic centrilobular region correlates
ith the changes seen histologically [10].Liver is the main target of pyrrolidine’s alkaloids, modifying
odium-potassium pump on liver’s membrane, causing endothe-
ial edema on the hepatic vein, stenosis of the centric hepatic
enous lumen, zone III necrosis and congestion of the hepatic

































Fig. 3. (a) Lobular center veinsclerosis. HE 200×.
sinusoids [11,12]. Mortality rate varies according cause, severity,
disease’s evolution and therapy instituted, but normally exceeds
40% [13,14]. The main clinical features are abdominal distention,
right hypochondrium pain, anorexia, malaise, ascites, jaundice and
hepatomegaly [15]. Most patients presents with symptoms within
one month after the ingestion. A significant portion of patients with
severe disease or without response to the treatment have progres-
sive exacerbations, complicated by infection – mostly respiratory
– and acute hepatic or renal failure, as our patient had [16].
HSOS may  be accompanied by progressive thrombocytope-
nia. The main hepatic manifestations are elevation of bilirubin,
cholestasis markers and aminotransaminases. Prothrombin time is
generally normal or slightly prolonged. Ascites usually had portal
hypertension characteristics, with a SAAG above 1.1 g/L [17].
Ultrasonography have a diagnosis value, depending on the
expertise of the physician. Typical findings include hepatomegaly,
splenomegaly, ascites, thickening of gallbladder’s walls, dilated
portal vein (>12 mm diameter) and narrowing of the hepatic veins
[18]. Abdominal CT often shows hepatomegaly, low density and
heterogeneity of hepatic parenchyma [19]. Hypodensity hepatic
areas, within the venous phase, correlate to blood stasis inside the
hepatic sinusoids [20,21]. Magnetic resonance’s findings are similar
[22,23].
HSOS differs from most other liver diseases in which circula-
tory changes are the cause rather than the consequence of the liver
injury. Impairment of circulation leads to hepatocyte necrosis and
eventual liver failure. Although early studies and the original name
of the disease (hepatic veno-occlusive disease) suggest that SOS
originates in the hepatic veins, analysis of clinical material demon-
strated that the critical change is obstruction at the sinusoids with
increased frequency of involvement of the central veins in more
severe cases [22,23].
Liver biopsy is an option to confirm the diagnosis in sus-
pected patients, mainly those with abnormal and atypical
laboratory/imaging findings, and shows significant dilation and
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nd necrosis of hepatocytes, interlobular veins’ endothelial cells
njury and edema. The first pathological changes involve dam-
ge to the microscopic anatomy of hepatic sinusoid endothelial
ells, followed by the development of hepatic sinusoid obstruc-
ion, endothelial cell damage, and impaired integrity of sinusoid
alls, with hepatic sinusoid congestion. Pathological manifesta-
ions in the acute phase include hepatocellular necrosis, endothelial
welling of the hepatic vein, thickening of the hepatic vein walls,
nd significant expansion and congestion of the sinuses. The patho-
ogical manifestations among patients in the subacute and chronic
hases included central lobular fibrosis and non-portal liver cirrho-
is, the latter particularly in the chronic phase [19,24,25].
The main treatment consists of suspending the agent causing
he syndrome. As with cirrhosis, spironolactone and furosemide
re good options for treatment of ascites and pleural effusions,
eserving TIPS to refractory ascites [7,26]. Hemodialysis should be
n option in case of systemic congestion or acute renal failure. The
ffectiveness of glucocorticoids is controversial. Pulse therapy can
e done, but the risk of infection should be considered, and the
egree of evidence is low [27]. Anticoagulant treatment is recom-
ended to be started as soon as possible in cases of acute/subacute
resentation. Contraindications include active hemorrhage or ten-
ency to bleeding. Low molecular weight heparin is the first choice,
ollowed by vitamin K antagonists, such as warfarin. The recom-
ended dosage for enoxaparin is 1 mg  BID, subcutaneously, and
he majority of patients do not need monitoring. Careful or avoid-
ng should be warranted in chronic renal failure patients. Warfarin
s the long term preferred drug, with a target International Nor-
alized Ratio between 2 and 3, for at least 3 months [28,29]. Liver
ransplantation should be considered to patients with acute liver
ailure who fail to respond to the clinical treatment [30].
Defibrotide, a complex of single-stranded oligodeoxyribonu-
leotides derived from porcine or bovine mucosal DNA, is the only
ffective drug indicated specific to HSOS treatment, but it’s not
idely available [31]. The mechanism of action is attributed to























S.T.A. Barcelos et al. 
endothelial cells [31]. A recent systematic analysis showed a 100-
day survival of 41–70% [32]. The high cost of defibrotide, however, is
an impediment for its use. This drug is not supplied in our healthy
system; therefore, it is difficult to use it promptly. Besides that,
the published studies and recommendations indicates that defi-
brotide is an effective therapy for the treatment of HSOS following
haemopoietic stem cell transplantation [8,33].
4. Conclusion
HSOS is a high mortality syndrome. This report highlights the
importance of considering this condition as a differential diagnosis
in patients with portal hypertension, and also the potential toxic
effect concerning use of medicinal plants.
Abbreviations
HSOS sinusoidal obstruction syndrome
PA pyrrolidine alkaloid
HCT hematopoietic cell transplantation
CMV  cytomegalovirus
CT computed tomography
SAAG serum-ascites albumin gradient
TIPS Transjugular Intrahepatic Portosystemic Shunt
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